Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jun;6(2):81-8.
doi: 10.1007/s11897-009-0013-9.

The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction

Affiliations
Review

The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction

Bing S Huang et al. Curr Heart Fail Rep. 2009 Jun.

Abstract

Following a myocardial infarction (MI), increases in plasma angiotensin II may activate central nervous system (CNS) pathways and thereby peripheral mechanisms (eg, sympathetic activity and the circulating/cardiac renin-angiotensin-aldosterone system ). Plasma angiotensin II may directly activate CNS pathways through the subfornical organ and chronically enhance activity by way of a neuromodulatory system. The latter involves an increase in CNS aldosterone-causing "ouabain" release (eg, from magnocellular neurons of the supraoptic and paraventricular nuclei). "Ouabain" may lower membrane potential, thereby enhancing activity of angiotensinergic pathways. The resulting increases in sympathetic activity, and circulating/cardiac RAAS contributes to progressive left ventricular remodeling and dysfunction after MI and can be largely prevented by central administration of a blocker for any of the components of this neuromodulatory system. These new insights into the crucial role of the CNS may lead to new therapeutic approaches for the prevention of heart failure after MI with minimal peripheral adverse effects.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Exp Hypertens. 1998 Feb;20(2):119-40 - PubMed
    1. Am J Physiol Regul Integr Comp Physiol. 2001 Nov;281(5):R1734-45 - PubMed
    1. Cardiovasc Res. 2009 Feb 15;81(3):574-81 - PubMed
    1. J Hypertens. 2006 Jun;24(6):1147-55 - PubMed
    1. Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R994-R1000 - PubMed

Publication types

MeSH terms

LinkOut - more resources